Patent · US Active

Diltiazem controlled release formulation and method of manufacture

US8778395B2 · kind B2 · utility

0Cited by

86References

5Claims

0Family size

Assignee

Andrx Labs, LLC · US

Inventors

Xiu Xiu Cheng · Pembroke Pines, US
Xiaohong Qi · Palatka, US
Guohua Zhang · Beijing, CN
Manesh Dixit · Sunrise, US

Key dates

Filing date	Aug 11, 2005
Grant date	Jul 15, 2014
Priority date	—
Expiry date	Oct 7, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/554
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A controlled release diltiazem dosage formulation comprising a plurality of diltiazem pellets and a gel-forming material where the time of maximum diltiazem blood plasma levels occurs more than 8 hours after administration and preferably more than 10 hours after administration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.